A new strategy to target regulatory T cells in solid tumors

Audrey Thomas-Schoemann,1,2,3,* Frédéric Batteux2 and Jérôme Alexandre2,4

1Université Paris Descartes; Unité de Formation et de Recherche des Sciences Pharmaceutiques et Biologiques; Paris, France; 2Université Paris Descartes; Sorbonne Paris Cité; Faculté de Médecine; Paris, France; 3Unité Fonctionnelle de Pharmacocinétique et Pharmacochimie; Assistance Publique-Hôpitaux de Paris; Hôpital Cochin; Paris, France; 4Service d’Oncologie; Assistance Publique-Hôpitaux de Paris; Groupement des Hôpitaux Paris Centre; Paris, France

Keywords: regulatory T cell, arsenic trioxide, colon cancer, oxidative stress, nitrosative stress, breast cancer

The depletion of regulatory T cells (Tregs) is a promising therapeutic strategy to enhance antitumor immune responses. Our recent findings indicate that low doses of arsenic trioxide can delay tumor growth in murine models of colon and breast cancer by depleting Tregs through oxidative and nitrosative bursts.

An increased number of regulatory T cells (Tregs) has been observed in the blood and tumor tissues of a high proportion of cancer patients, a phenomenon that promotes tumor progression and adversely affects prognosis.1 Tregs express a series of markers including CD4, CD25 and the transcription factor FOXP3, which enables cells to suppress immune responses. The adverse effects of Tregs on the immune response are underscored by the observation that Treg depletion can enhance the efficacy of immunotherapeutic strategies.2 Cyclophosphamide (CPM), a DNA alkylating agent, is used in numerous chemotherapy regimens. Clinical data reveal that although high-dose CPM exert potent immunosuppressive effects, low-dose CPM has an immunostimulatory activity. In this context, it has been shown that low-dose CPM decreases the number of Tregs and hence can enhance the antitumor activity of adoptively transferred T cells as well as of antitumor vaccines.3

Several strategies have been or are being developed to target Tregs. Two different human anti-CD25 antibodies (basiliximab and daclizumab) and the recombinant interleukin (IL)-2-diphtheria toxin conjugate known as denileukin diftitox are currently under development. Ipilimumab, a monoclonal antibody targeting CTLA-4 (which is required for Treg function), has provided impressive results in advanced melanoma patients.2 Finally, as outlined in a review by Galluzzi et al., several others targeted agents stimulate tumor-specific immune responses, and some of them have been associated with decreased levels of circulating or tumor-infiltrating Tregs.4 More specifically, a recent study has revealed that targeted agents that block the vascular endothelial growth factor A (VEGFA)/VEGF receptor 2 (VEGFR2) axis (e.g., bevacizumab and sunitinib) inhibit Treg proliferation triggered by VEGFA.5

Arsenic trioxide ($\text{As}_2\text{O}_3$) has been associated with substantial clinical efficacy in the treatment of promyelocytic leukemia patients. In addition, preclinical studies have shown that other hematological cancer and solid tumors are susceptible to $\text{As}_2\text{O}_3$. Although the exact mechanisms underlying the antitumor effects of this agent remain unclear, $\text{As}_2\text{O}_3$ has been recognized as a powerful inducer of oxidative stress in tumor cells.6

We recently demonstrated that low-dose $\text{As}_2\text{O}_3$ increases antitumor immune response in colon tumor-bearing mice by modulating Treg abundance.7 We first observed that tumor-bearing mice display an increased proportion of Tregs among the splenic CD4+ cell population, contributing to immune escape. We showed that $\text{As}_2\text{O}_3$ induces the selective depletion of Tregs both in vitro and in vivo. Indeed, $\text{As}_2\text{O}_3$ depleted Tregs in both the spleen and the tumor tissues of mice bearing murine colon carcinoma CT26 cells. Low-dose $\text{As}_2\text{O}_3$ was found to exert antitumor effects that are closely related to Treg depletion in both colon (CT26 cells) and breast (4T1 cells) carcinoma murine models. $\text{As}_2\text{O}_3$ turned out to be able to restore the activity of immune cells adoptively transferred from donor mice, thus enhance their antitumor potential. Our results confirmed a previous study that had revealed that $\text{As}_2\text{O}_3$ can exacerbate immune responses against breast cancer cells.8 In this study, $\text{As}_2\text{O}_3$ was shown to increase the cytotoxicity of lymphokine-activated killer (LAK) cells. Tregs were not specifically explored, but they are well known to affect the antitumor activity of multiple effector cells, including LAK cells.

We observed immunostimulatory effects at low $\text{As}_2\text{O}_3$ concentrations (0.5–1 μM) in vitro and with a single 1 mg/Kg dose in vivo. In previous studies, $\text{As}_2\text{O}_3$ doses ranging from 2 to 6.5 mg/Kg/day for one to six weeks were required to obtained therapeutic effects against solid tumors.9 The immunogenic effects of low-dose $\text{As}_2\text{O}_3$ appear to be related to the high sensitivity of Tregs to this agent. It has previously been shown...
that low-dose CPM similarly decreases the number of Tregs. However, CPM may exert a toxic effect on other lymphocyte populations. Indeed, we observed that CPM induces a splenocyte depletion that could not be observed with As$_2$O$_3$ These data suggest that the specificity of As$_2$O$_3$ for Tregs may be higher than that of CPM.

Finally, we demonstrated that the depletion of Tregs as induced by As$_2$O$_3$ is mediated by the generation of reactive oxygen and nitrogen species. We showed that As$_2$O$_3$ promotes the accumulation of hydrogen peroxide (H$_2$O$_2$) and/or peroxynitrite (ONOO$^-$) in Tregs, as demonstrated via the fluorescent probe H$_2$DCFDA (2’7’-dichlorodihydrofluorescein diacetate). Our data strongly suggest that Treg depletion as induced by As$_2$O$_3$ is related to ONOO$^-$ production, because it was inhibited by the nitric oxide (NO) synthase inhibitor NG-nitro-l-arginine methyl ester (L-NAME) and by the SOD mimic manganese [III] tetrakis-(5,10,15,20)-benzoic acid porphyrin (MnTBAP) (Fig. 1).

Thus, Treg depletion as induced by As$_2$O$_3$ is related to superoxide and NO production resulting in the accumulation of ONOO$^-$. In contrast, As$_2$O$_3$ failed to induce ONOO$^-$ accumulation, as demonstrated via the fluorescent probe MitoSOX. Therefore, As$_2$O$_3$ is able to induce the intracellular accumulation of superoxide anion (O$_2^-$) and nitrite oxide (NO). Superoxide dismutases (SODs) catalyze the dismutation of O$_2^-$ in hydrogen peroxide (H$_2$O$_2$), which is converted in H$_2$O by catalase and glutathione peroxidase. O$_2^-$ may also react with NO to form peroxynitrite (ONOO$^-$). Our data suggest that the depletion of regulatory T cells (Tregs) as induced by As$_2$O$_3$ is related to O$_2^-$ and NO production, resulting in ONOO$^-$ accumulation, as it is limited by the NO synthase (NOS) inhibitor NG-nitro-l-arginine methyl ester (L-NAME) and by the SOD mimic manganese [III] tetrakis-(5,10,15,20)-benzoic acid porphyrin (MnTBAP).

In conclusion, we suggest for the first time that low doses of As$_2$O$_3$ may constitute a new strategy to deplete Tregs in colorectal tumors. Indeed, we have recently shown that As$_2$O$_3$ can deplete Tregs through oxidative and nitrosative bursts, thus improving antitumor immune responses. Our results offer a new opportunity to use low doses of As$_2$O$_3$ to enhance the antitumor activity of adoptive immunotherapy against human cancer.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

1. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Moertram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093.

2. Mougiakakos D, Choudhary A, Llader A, Kiessling R, Johansson CC. Regulatory T cells in cancer. Adv Cancer Res 2010; 107:57-117; PMID:20999961; http://dx.doi.org/10.1016/S0065-230X(10)07003-X.

3. Bracci L, Moschella F, Sesti P, La Sorsa V, Valentini M, Canini I, et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytotoxic expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 2007; 13:644-53; PMID:17255288; http://dx.doi.org/10.1158/1078-0432.CCR-06-1209.

4. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626.

5. Terme M, Pernet S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, et al. VEGFA-VEGF Receptor pathway blockade inhibits tumor-induced regulatory T cell proliferation in colorectal cancer. Cancer Res 2012; In Press; PMID:23108136; http://dx.doi.org/10.1158/0008-5472.CAN-12-2325.

6. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeu tic approach? Nat Rev Drug Discov 2009; 8:675-91; PMID:19478820; http://dx.doi.org/10.1038/nrd2803.

7. Thomas-Schoemann A, Barreteau F, Mongaret A, Nicco C, Chéreau C, Amnouez M, et al. Arsenic Trioxide Exerts Antitumor Activity through Regulatory T Cell Depletion Mediated by Oxidative Stress in a Murine Model of Colon Cancer. J Immunol 2012; 189:5171-7; PMID:23105136; http://dx.doi.org/10.4049/jimmunol.1103094.

8. Bag G, Arulopu A, Deaglio S, Mallone R, Vigone A, De Cesare MG, et al. Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 2002; 73:51-53; PMID:12080266; http://dx.doi.org/10.1023/A:1015272401822.

9. Liu B, Pan S, Dong X, Qiao H, Jiang H, Krissansen GL, et al. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci 2006; 97:675-81; PMID:16827809; http://dx.doi.org/10.1111/j.1349-7006.2006.00230.x.

10. Wang J, Li L, Gang H, Shi G, Yi J. NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells. Leuk Res 2008; 32:429-36; PMID:17804067; http://dx.doi.org/10.1016/j.leukres.2007.06.006.